Anti-Rheumatic Rx
On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these as their favorite reports:
DAS-28 independently associated survival in RA-ILD. As I keep saying, treating the…
Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites:
Secukinumab Efficacy in Enthesitis-Related and Juvenile Psoriatic Arthritis.
Abstract 1424 – Dr. Hermine…
2 years 5 months ago
Thank you @AhmadSherbini for discussing his #ACR21 research on @RheumNow on Abs#1444 - Can we predict which patients are most likely to have nausea or alopecia intolerance to MTX?
https://t.co/I5WmCECq7v
2 years 5 months ago
Racial disparities & Co-morbidities in PsA findings. Amongst important others, increased biologic use in Caucasians w/ PsA vs DMARDs in black PsA pts. View Abs 1780 for other relevant findings. #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/0uKsa8i0bG https://t.co/R9YkxYqXws
2 years 5 months ago
Methotrexate did not improve Ustekinumab efficacy in tx of PsA
⭐️Addition of MTX did not improve dactylitis, enthesitis, skin, QoL or function
#ACR21 #ACRBest @RheumNow
Abs#L12
https://t.co/6dxWPNskou https://t.co/BnzH8PfaMV
2 years 5 months ago
No benefit to using MTX in combination with ustekinumab in PsA. No difference in efficacy for arthritis, enthesitis, dactylitis, skin, QoL or function. Abstr#L12 #ACR21 @RheumNow https://t.co/iojKLqRb06
Poster Hall